Biomea Fusion, Inc.

BMEA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001840439

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $58.6M
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 24, 2026 225 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$0.63 2026-11-03; market equity $45.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 24, 2026

We are a clinical?stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 92.8						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	12.4%	(6.6%)		92.8	803	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 56.8						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(28.25)	(0.35)		79.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	5.23x	2.92x		34.3	828	2025-12-31
Growth and financing, sleeve percentile 84.3						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(23.2%)	2.2%		87.1	697	2025-12-31
Net share issuance, one year	92.4%	2.5%		81.6	632	2026-03-20

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 92.4%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(2.2%)	(2.2%)	50
Distance from 52-week high	(71.8%)	(29.8%)	12
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(266.0%)	(0.9%)	3
Book value to price	0.27	0.28	49
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.19)	(0.19)	50

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$34.8M
Operating cash flow, four quarters	-$47.2M
Months of runway	8.9
Days since last periodic filing	91 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$2.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$61.8M	2025-12-31	2026-03-24	10-K	26-121825
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$70.4M	2025-12-31	2026-03-24	10-K	26-121825
3	assets	us-gaap:Assets	$58.6M	2025-12-31	2026-03-24	10-K	26-121825
4	assets	us-gaap:Assets	$79.9M	2024-12-31	2026-03-24	10-K	26-121825
5	current assets	us-gaap:AssetsCurrent	$58.0M	2025-12-31	2026-03-24	10-K	26-121825
6	current liabilities	us-gaap:LiabilitiesCurrent	$11.1M	2025-12-31	2026-03-24	10-K	26-121825
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$449.0M	2025-12-31	2026-03-24	10-K	26-121825
8	operating income	us-gaap:OperatingIncomeLoss	-$83.5M	2025-12-31	2026-03-24	10-K	26-121825
9	book equity	us-gaap:StockholdersEquity	$29.6M	2025-12-31	2026-03-24	10-K	26-121825
10	liabilities	us-gaap:Liabilities	$29.0M	2025-12-31	2026-03-24	10-K	26-121825
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$119.9M	2024-12-31	2026-03-24	10-K	26-121825
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$362,000	2024-12-31	2026-03-24	10-K	26-121825
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$96.6M	2023-12-31	2026-03-24	10-K	26-121825
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.4M	2023-12-31	2026-03-24	10-K	26-121825
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$62.4M	2022-12-31	2025-03-31	10-K	25-047775
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.0M	2022-12-31	2025-03-31	10-K	25-047775
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$35.4M	2021-12-31	2024-03-28	10-K	24-038026
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.2M	2021-12-31	2024-03-28	10-K	24-038026
19	assets	us-gaap:Assets	$199.9M	2023-12-31	2025-03-31	10-K	25-047775
20	assets	us-gaap:Assets	$129.3M	2022-12-31	2024-03-28	10-K	24-038026
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	72,299,440	2026-03-20	2026-03-24	10-K	26-121825
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	37,572,250	2025-03-24	2025-03-31	10-K	25-047775

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.